These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 31231766)

  • 41. Localised Mycobacterium ulcerans infection in four dogs.
    O'Brien CR; McMillan E; Harris O; O'Brien DP; Lavender CJ; Globan M; Legione AR; Fyfe JA
    Aust Vet J; 2011 Dec; 89(12):506-10. PubMed ID: 22103951
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Clinical, microbiological and pathological findings of Mycobacterium ulcerans infection in three Australian Possum species.
    O'Brien CR; Handasyde KA; Hibble J; Lavender CJ; Legione AR; McCowan C; Globan M; Mitchell AT; McCracken HE; Johnson PD; Fyfe JA
    PLoS Negl Trop Dis; 2014; 8(1):e2666. PubMed ID: 24498451
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Clinical and bacteriological efficacy of rifampin-streptomycin combination for two weeks followed by rifampin and clarithromycin for six weeks for treatment of Mycobacterium ulcerans disease.
    Phillips RO; Sarfo FS; Abass MK; Abotsi J; Wilson T; Forson M; Amoako YA; Thompson W; Asiedu K; Wansbrough-Jones M
    Antimicrob Agents Chemother; 2014; 58(2):1161-6. PubMed ID: 24323473
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Delayed versus standard assessment for excision surgery in patients with Buruli ulcer in Benin: a randomised controlled trial.
    Wadagni AC; Barogui YT; Johnson RC; Sopoh GE; Affolabi D; van der Werf TS; de Zeeuw J; Kleinnijenhuis J; Stienstra Y
    Lancet Infect Dis; 2018 Jun; 18(6):650-656. PubMed ID: 29605498
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Findings in patients from Benin with osteomyelitis and polymerase chain reaction-confirmed Mycobacterium ulcerans infection.
    Pommelet V; Vincent QB; Ardant MF; Adeye A; Tanase A; Tondeur L; Rega A; Landier J; Marion E; Alcaïs A; Marsollier L; Fontanet A; Chauty A
    Clin Infect Dis; 2014 Nov; 59(9):1256-64. PubMed ID: 25048846
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Paradoxical reactions in Buruli ulcer after initiation of antibiotic therapy: Relationship to bacterial load.
    Frimpong M; Agbavor B; Duah MS; Loglo A; Sarpong FN; Boakye-Appiah J; Abass KM; Dongyele M; Amofa G; Tuah W; Frempong M; Amoako YA; Wansbrough-Jones M; Phillips RO
    PLoS Negl Trop Dis; 2019 Aug; 13(8):e0007689. PubMed ID: 31449522
    [TBL] [Abstract][Full Text] [Related]  

  • 47. "Paradoxical" immune-mediated reactions to Mycobacterium ulcerans during antibiotic treatment: a result of treatment success, not failure.
    O'Brien DP; Robson ME; Callan PP; McDonald AH
    Med J Aust; 2009 Nov; 191(10):564-6. PubMed ID: 19912091
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Increased Severity and Spread of Mycobacterium ulcerans, Southeastern Australia.
    Tai AYC; Athan E; Friedman ND; Hughes A; Walton A; O'Brien DP
    Emerg Infect Dis; 2018 Jan; 24(1):58-64. PubMed ID: 28980523
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Corticosteroid-induced immunosuppression ultimately does not compromise the efficacy of antibiotherapy in murine Mycobacterium ulcerans infection.
    Martins TG; Trigo G; Fraga AG; Gama JB; Longatto-Filho A; Saraiva M; Silva MT; Castro AG; Pedrosa J
    PLoS Negl Trop Dis; 2012; 6(11):e1925. PubMed ID: 23209864
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Microbiology of secondary infections in Buruli ulcer lesions; implications for therapeutic interventions.
    Gyamfi E; Narh CA; Quaye C; Abbass A; Dzudzor B; Mosi L
    BMC Microbiol; 2021 Jan; 21(1):4. PubMed ID: 33402095
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Chronic wounds in Sierra Leone: Searching for Buruli ulcer, a NTD caused by Mycobacterium ulcerans, at Masanga Hospital.
    Please HR; Vas Nunes JH; Patel R; Pluschke G; Tholley M; Ruf MT; Bolton W; Scott JA; Grobusch MP; Bolkan HA; Brown JM; Jayne DG
    PLoS Negl Trop Dis; 2021 Oct; 15(10):e0009862. PubMed ID: 34644298
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Paradoxical responses after start of antimicrobial treatment in Mycobacterium ulcerans infection.
    Nienhuis WA; Stienstra Y; Abass KM; Tuah W; Thompson WA; Awuah PC; Awuah-Boateng NY; Adjei O; Bretzel G; Schouten JP; van der Werf TS
    Clin Infect Dis; 2012 Feb; 54(4):519-26. PubMed ID: 22156855
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Co-infection of HIV in patients with Buruli ulcer disease in Central Ghana.
    Amoako YA; Loglo AD; Frimpong M; Agbavor B; Abass MK; Amofa G; Ofori E; Ampadu E; Asiedu K; Stienstra Y; Wansbrough-Jones M; van der Werf T; Phillips RO
    BMC Infect Dis; 2021 Apr; 21(1):331. PubMed ID: 33832460
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Clinical efficacy of combination of rifampin and streptomycin for treatment of Mycobacterium ulcerans disease.
    Sarfo FS; Phillips R; Asiedu K; Ampadu E; Bobi N; Adentwe E; Lartey A; Tetteh I; Wansbrough-Jones M
    Antimicrob Agents Chemother; 2010 Sep; 54(9):3678-85. PubMed ID: 20566765
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Activities of rifampin, Rifapentine and clarithromycin alone and in combination against mycobacterium ulcerans disease in mice.
    Almeida D; Converse PJ; Ahmad Z; Dooley KE; Nuermberger EL; Grosset JH
    PLoS Negl Trop Dis; 2011 Jan; 5(1):e933. PubMed ID: 21245920
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The compound TB47 is highly bactericidal against Mycobacterium ulcerans in a Buruli ulcer mouse model.
    Liu Y; Gao Y; Liu J; Tan Y; Liu Z; Chhotaray C; Jiang H; Lu Z; Chiwala G; Wang S; Makafe G; Islam MM; Hameed HMA; Cai X; Wang C; Li X; Tan S; Zhang T
    Nat Commun; 2019 Jan; 10(1):524. PubMed ID: 30705268
    [TBL] [Abstract][Full Text] [Related]  

  • 57. High-Dose Rifamycins Enable Shorter Oral Treatment in a Murine Model of Mycobacterium ulcerans Disease.
    Omansen TF; Almeida D; Converse PJ; Li SY; Lee J; Stienstra Y; van der Werf T; Grosset JH; Nuermberger EL
    Antimicrob Agents Chemother; 2019 Feb; 63(2):. PubMed ID: 30455239
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Targeting the Mycobacterium ulcerans cytochrome bc
    Scherr N; Bieri R; Thomas SS; Chauffour A; Kalia NP; Schneide P; Ruf MT; Lamelas A; Manimekalai MSS; Grüber G; Ishii N; Suzuki K; Tanner M; Moraski GC; Miller MJ; Witschel M; Jarlier V; Pluschke G; Pethe K
    Nat Commun; 2018 Dec; 9(1):5370. PubMed ID: 30560872
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Challenges Associated with Management of Buruli Ulcer/Human Immunodeficiency Virus Coinfection in a Treatment Center in Ghana: A Case Series Study.
    Tuffour J; Owusu-Mireku E; Ruf MT; Aboagye S; Kpeli G; Akuoku V; Pereko J; Paintsil A; Bonney K; Ampofo W; Pluschke G; Yeboah-Manu D
    Am J Trop Med Hyg; 2015 Aug; 93(2):216-23. PubMed ID: 26055745
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Recent advances in leprosy and Buruli ulcer (Mycobacterium ulcerans infection).
    Walsh DS; Portaels F; Meyers WM
    Curr Opin Infect Dis; 2010 Oct; 23(5):445-55. PubMed ID: 20581668
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.